These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 33084053)

  • 1. Evaluating the impact of antiretroviral and antiseizure medication interactions on treatment effectiveness among outpatient clinic attendees with HIV in Zambia.
    Navis A; Dallah I; Mabeta C; Musukuma K; Siddiqi OK; Bositis CM; Koralnik IJ; Gelbard HA; Theodore WH; Okulicz JF; Johnson BA; Sikazwe I; Bearden DR; Birbeck GL
    Epilepsia; 2020 Dec; 61(12):2705-2711. PubMed ID: 33084053
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence of nonsuppressed viral load and associated factors among HIV-positive adults receiving antiretroviral therapy in Eswatini, Lesotho, Malawi, Zambia and Zimbabwe (2015 to 2017): results from population-based nationally representative surveys.
    Haas AD; Radin E; Hakim AJ; Jahn A; Philip NM; Jonnalagadda S; Saito S; Low A; Patel H; Schwitters AM; Rogers JH; Frederix K; Kim E; Bello G; Williams DB; Parekh B; Sachathep K; Barradas DT; Kalua T; Birhanu S; Musuka G; Mugurungi O; Tippett Barr BA; Sleeman K; Mulenga LB; Thin K; Ao TT; Brown K; Voetsch AC; Justman JE
    J Int AIDS Soc; 2020 Nov; 23(11):e25631. PubMed ID: 33225559
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12 286/MOBIDIP): a multicentre, randomised, parallel, open-label, superiority trial.
    Ciaffi L; Koulla-Shiro S; Sawadogo AB; Ndour CT; Eymard-Duvernay S; Mbouyap PR; Ayangma L; Zoungrana J; Gueye NFN; Diallo M; Izard S; Bado G; Kane CT; Aghokeng AF; Peeters M; Girard PM; Le Moing V; Reynes J; Delaporte E;
    Lancet HIV; 2017 Sep; 4(9):e384-e392. PubMed ID: 28566227
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An evaluation of antiretroviral HIV/AIDS treatment in a Rio de Janeiro public clinic.
    Carmody ER; Diaz T; Starling P; dos Santos AP; Sacks HS
    Trop Med Int Health; 2003 May; 8(5):378-85. PubMed ID: 12753630
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of the frequency of plasma viral load monitoring on treatment outcomes among children with perinatally acquired HIV.
    Sudjaritruk T; Boettiger DC; Nguyen LV; Mohamed TJ; Wati DK; Bunupuradah T; Hansudewechakul R; Ly PS; Lumbiganon P; Nallusamy RA; Fong MS; Chokephaibulkit K; Nik Yusoff NK; Truong KH; Do VC; Sohn AH; Sirisanthana V;
    J Int AIDS Soc; 2019 Jun; 22(6):e25312. PubMed ID: 31179641
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dolutegravir-lamivudine as initial therapy in HIV-1 infected, ARV-naive patients, 48-week results of the PADDLE (Pilot Antiretroviral Design with Dolutegravir LamivudinE) study.
    Cahn P; Rolón MJ; Figueroa MI; Gun A; Patterson P; Sued O
    J Int AIDS Soc; 2017 May; 20(1):21678. PubMed ID: 28537061
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Short communication: Lower baseline CD4 count is associated with a greater propensity toward virological failure in a cohort of South African HIV patients.
    Costiniuk CT; Sigal A; Jenabian MA; Nijs P; Wilson D
    AIDS Res Hum Retroviruses; 2014 Jun; 30(6):531-4. PubMed ID: 24803320
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lability of antiretroviral drug resistance mutations--correlates with immunological and virological responses.
    Al Mazari A; Zomaya AY; Charleston M; Salem H; Maher A; Garsia RJ
    Curr HIV Res; 2007 Jul; 5(4):430-9. PubMed ID: 17627506
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevention of mother-to-child transmission of HIV in Zambia: implementing efficacious ARV regimens in primary health centers.
    Mandala J; Torpey K; Kasonde P; Kabaso M; Dirks R; Suzuki C; Thompson C; Sangiwa G; Mukadi YD
    BMC Public Health; 2009 Aug; 9():314. PubMed ID: 19712454
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-world effectiveness and tolerability of switching to doravirine-based antiretroviral therapy in people with HIV: a nationwide, matched, prospective cohort study.
    Oomen PGA; Wit FWNM; Brinkman K; Vrouenraets SME; Mudrikova T; van Welzen BJ; van der Valk M;
    Lancet HIV; 2024 Sep; 11(9):e576-e585. PubMed ID: 39209387
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High prevalence of HIV-1 drug resistance among patients on first-line antiretroviral treatment in Lomé, Togo.
    Dagnra AY; Vidal N; Mensah A; Patassi A; Aho K; Salou M; Monleau M; Prince-David M; Singo A; Pitche P; Delaporte E; Peeters M
    J Int AIDS Soc; 2011 Jun; 14():30. PubMed ID: 21663632
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Carbamazepine--indinavir interaction causes antiretroviral therapy failure.
    Hugen PW; Burger DM; Brinkman K; ter Hofstede HJ; Schuurman R; Koopmans PP; Hekster YA
    Ann Pharmacother; 2000 Apr; 34(4):465-70. PubMed ID: 10772431
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical manifestations and treatment outcomes in HIV-1-infected children receiving antiretroviral therapy in Karachi, Pakistan.
    Mir F; Qamar FN; Baig-Ansari N; Abro AG; Abbas SQ; Kazi MA; Rizvi A; Zaidi AK
    J Infect Dev Ctries; 2014 Apr; 8(4):519-25. PubMed ID: 24727519
    [TBL] [Abstract][Full Text] [Related]  

  • 14. One-, two-, and three-class resistance among HIV-infected patients on antiretroviral therapy in private care clinics: Mumbai, India.
    Gupta A; Saple DG; Nadkarni G; Shah B; Vaidya S; Hingankar N; Chaturbhuj D; Deshmukh P; Walshe L; Hudelson SE; James M; Paranjape RS; Eshleman SH; Tripathy S
    AIDS Res Hum Retroviruses; 2010 Jan; 26(1):25-31. PubMed ID: 20063995
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dolutegravir-based monotherapy or dual therapy maintains a high proportion of viral suppression even in highly experienced HIV-1-infected patients.
    Gubavu C; Prazuck T; Niang M; Buret J; Mille C; Guinard J; Avettand-Fènoël V; Hocqueloux L
    J Antimicrob Chemother; 2016 Apr; 71(4):1046-50. PubMed ID: 26712907
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Guidelines for using antiretroviral agents among HIV-infected adults and adolescents.
    Dybul M; Fauci AS; Bartlett JG; Kaplan JE; Pau AK;
    Ann Intern Med; 2002 Sep; 137(5 Pt 2):381-433. PubMed ID: 12617573
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Guidelines for using antiretroviral agents among HIV-infected adults and adolescents. Recommendations of the Panel on Clinical Practices for Treatment of HIV.
    Dybul M; Fauci AS; Bartlett JG; Kaplan JE; Pau AK;
    MMWR Recomm Rep; 2002 May; 51(RR-7):1-55. PubMed ID: 12027060
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of HIV-1 infection with a combination of nevirapine, stavudine, and lamivudine: a preliminary report on the Nigerian antiretroviral program.
    Idigbe EO; Adewole TA; Eisen G; Kanki P; Odunukwe NN; Onwujekwe DI; Audu RA; Araoyinbo ID; Onyewuche JI; Salu OB; Adedoyin JA; Musa AZ
    J Acquir Immune Defic Syndr; 2005 Sep; 40(1):65-9. PubMed ID: 16123684
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Virological response and resistance profiles after 24 months of first-line antiretroviral treatment in adults living in Bangui, Central African Republic.
    Péré H; Charpentier C; Mbelesso P; Dandy M; Matta M; Moussa S; De Dieu Longo J; Grésenguet G; Abraham B; Bélec L
    AIDS Res Hum Retroviruses; 2012 Apr; 28(4):315-23. PubMed ID: 21942692
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early virologic failure and the development of antiretroviral drug resistance mutations in HIV-infected Ugandan children.
    Ruel TD; Kamya MR; Li P; Pasutti W; Charlebois ED; Liegler T; Dorsey G; Rosenthal PJ; Havlir DV; Wong JK; Achan J
    J Acquir Immune Defic Syndr; 2011 Jan; 56(1):44-50. PubMed ID: 21099693
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.